Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$6.85 -4.9%	$6.35	$4.66 ▼ $7.86	$112.51M	0.58	16,703 shs	12,069 shs
CRBP Corbus Pharmaceuticals	$8.72 -1.2%	$7.27	$4.64 ▼ $61.90	$106.06M	3.11	349,496 shs	65,385 shs
PASG Passage Bio	$0.41 +4.3%	$0.37	$0.26 ▼ $1.33	$25.36M	1.71	361,184 shs	112,004 shs
TNYA Tenaya Therapeutics	$0.62 +5.2%	$0.48	$0.36 ▼ $4.06	$101.18M	2.91	2.61 million shs	1.57 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	0.00%	+3.45%	+10.77%	+21.21%	+719,999,900.00%
CRBP Corbus Pharmaceuticals	0.00%	-4.33%	+20.30%	+26.87%	-82.38%
PASG Passage Bio	0.00%	-7.52%	+29.47%	+0.26%	-62.76%
TNYA Tenaya Therapeutics	0.00%	-6.67%	+31.56%	-18.97%	-82.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	3.9772 of 5 stars	3.6	1.0	0.0	4.7	3.0	2.5	0.0
PASG Passage Bio	2.809 of 5 stars	3.5	2.0	0.0	0.0	2.7	1.7	1.3
TNYA Tenaya Therapeutics	3.6976 of 5 stars	3.5	3.0	0.0	0.0	2.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	99.51% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	483.23% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,738.24% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	904.82% Upside

Current Analyst Ratings Breakdown

Latest PASG, BHST, CRBP, and TNYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/31/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$27.70M	4.06	N/A	N/A	($1.08) per share	-6.34
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	($1.56) per share	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$2.03 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$2.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.56M	-$0.50	N/A	N/A	N/A	-76.65%	N/A	-85.16%	8/14/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$44.60M	-$4.22	N/A	N/A	N/A	N/A	-42.28%	-32.92%	8/5/2025 (Estimated)
PASG Passage Bio	-$102.06M	-$1.02	N/A	N/A	N/A	N/A	-72.53%	-52.10%	8/6/2025 (Estimated)
TNYA Tenaya Therapeutics	-$124.08M	-$1.16	N/A	N/A	N/A	N/A	-86.17%	-71.14%	8/14/2025 (Estimated)

Latest PASG, BHST, CRBP, and TNYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million
3/17/2025	Q4 2024	TNYA Tenaya Therapeutics	-$0.32	-$0.28	+$0.04	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.80	0.48
CRBP Corbus Pharmaceuticals	N/A	13.84	13.84
PASG Passage Bio	N/A	5.15	5.15
TNYA Tenaya Therapeutics	N/A	5.27	5.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
CRBP Corbus Pharmaceuticals	64.64%
PASG Passage Bio	53.48%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
CRBP Corbus Pharmaceuticals	3.60%
PASG Passage Bio	5.00%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
CRBP Corbus Pharmaceuticals	40	12.24 million	11.69 million	Optionable
PASG Passage Bio	130	62.15 million	59.11 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	53.27 million	Optionable

PASG, BHST, CRBP, and TNYA Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Analysts

June 12, 2025 | marketbeat.com

Head-To-Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Alpha Cognition (NASDAQ:ACOG)

June 12, 2025 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short Interest

June 2, 2025 | marketbeat.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.com

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.com

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.com

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025 | globenewswire.com

Tenaya Slashes a Third of Workforce to Fund Development of Cardio Gene Therapies

April 1, 2025 | biospace.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%

April 1, 2025 | aaii.com

Tenaya data further builds TN-201 profile, says H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, BHST, CRBP, and TNYA Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$6.85 -0.35 (-4.86%)

As of 03:30 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Corbus Pharmaceuticals NASDAQ:CRBP

$8.72 -0.11 (-1.21%)

As of 03:59 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Passage Bio NASDAQ:PASG

$0.41 +0.02 (+4.35%)

As of 03:59 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Tenaya Therapeutics NASDAQ:TNYA

$0.62 +0.03 (+5.16%)

As of 03:59 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time